E. CUAJ, “Enfortumab Vedotin (EV) and Pembrolizumab (Pembro) Combination Treatment for Patients with Urological Cancers – Adverse Events (AEs): Management Tool Kit”, CUAJ, vol. 15, no. 1X, May 2026.